China Healthcare Stocks Beat Earnings Expectations, Leading MSCI China in Valuation Recovery
Nashnova编辑部
China's healthcare sector has surged over 30% since its early-June low, ranking first among MSCI China's 11 industry groups while the benchmark gained just ~1%. This means → capital is rotating out of richly valued tech into healthcare names with improving fundamentals.
How strong is this rally, really?
The MSCI China healthcare sub-index is up over 30% from its early-June trough — the only sector with positive returns over the past three months.
Tech stocks fell roughly 5% over the same period. The divergence makes the rotation unmistakable.
This reflects a market-wide "de-foaming" — money is leaving overvalued AI plays and moving toward companies with real earnings improvement.
Who is leading, and on what basis?
Two lines are driving the gains: CDMO — contract research and manufacturing organizations that outsource drug R&D and production — and innovative pharma companies.
WuXi AppTec, the CDMO leader, reported first-half results above consensus and raised full-year guidance; its stock surged, making it one of the sub-index's top gainers.
CSPC Pharmaceutical's innovative-drug arm also ranked among the top performers. In plain terms = this rally is not a sector-wide tide — it rewards companies that delivered strong results.
After a 30% run, is the sector still cheap?
The current P/E sits below 26× on forward earnings, still under the 28× ten-year average and far below the near-68× peak of 2021.
This means → even after a 30% rally, healthcare remains "below the historical mean" — it has not yet entered expensive territory.
AllianceBernstein CIO John Lin put it bluntly: "After a quarter of AI frenzy, you suddenly find companies with solid fundamentals trading at valuations that look more like value stocks."
Has the long-term thesis for China healthcare changed?
China now accounts for roughly one-third of the global innovative-drug pipeline and is the world's top destination by clinical-trial volume.
Fidelity International research director Monica Li notes China is shifting from "manufacturing base" to "global source of new-drug R&D," while global biotech funding conditions have clearly improved.
This reflects a structural shift: Chinese healthcare is no longer just "cheap contract work" — it is beginning to export home-grown innovation.
Is this a full-blown bull market? What to watch next week?
Janus Henderson Greater China equities head Victoria Mio is explicit: "I would not characterize this as a broad healthcare bull market. It remains selective."
She notes investors are rigorously screening for earnings visibility, pipeline quality, identifiable catalysts, and balance-sheet strength — not every healthcare name is rallying.
Next week, Hengrui Medicine and CSPC Pharmaceutical report earnings — a key test of whether this valuation recovery can find broader fundamental support.
Content is for reference only, not financial advice.